Comparison of the clinical and radiological manifestations of male patients with COVID-19 from different ethnicities

AIM

The coronavirus disease 2019 (COVID-19) outbreak began in Wuhan, China, and quickly escalated into a significant pandemic threat. COVID-19 is associated with variable morbidity and mortality rates, which differ greatly from one country to another. This study aimed to investigate the clinical findings of SARS-CoV-2 infection in different ethnic groups, as well as to identify the radiological manifestations and various biomarkers for the assessment of COVID-19 patients.

MATERIALS AND METHODS

The clinical data of 210 COVID-19 patients with respiratory disorders, who attended the chest clinic at Mouwasat Hospital, Jubail, in the Eastern area of the Kingdom of Saudi Arabia from April to May 2020, were thoroughly reviewed. The patients were divided into seven groups based on their ethnicities (Saudi, Egyptian, Nepali, Filipino, Pakistani, Bangladeshi and Indian). The differences in the clinical findings, laboratory data and radiological manifestations between these groups were statistically analysed.

RESULTS

The study included 210 COVID-19 patients from seven ethnic groups (Saudi, Egyptian, Nepali, Filipino, Pakistani, Bangladeshi and Indian). Comorbidities were reported among 60.9% of patients, which were significantly higher among Filipinos at 73.3%. Dyspnoea was prevalent in the Saudi and Pakistani groups, while hypoxaemia was prevalent in the Indian group (40%). In terms of laboratory assessment, Bangladesh patients had the highest median of serum ferritin and lactate dehydrogenase (LDH) levels with a significant P value (<.001), while Saudi patients had the highest median of C-reactive protein (CRP) levels with a significant P value (<.001). According to computed tomography (CT) findings, structural destruction was the most common finding in bilateral parenchymal affection among 88.6% of patients. Filipinos and Bangladeshis had the highest morbidity rates.

CONCLUSION

There were great variations in clinical, radiological and even laboratory findings among different ethnic groups of COVID-19 patients.

Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer

•

MP-MRI will play a major role in next decades for early detection, characterization, and local and even distant staging of prostate cancer.

•

mp-MRI of prostate using PI-RADS v2 scoring system proved high sensitivity and specificity in diagnosis of prostate cancer.

•

SO PI-RADS v2 scoring system using mp-MRI recommended as non-invasive diagnostic tool correlated to TRUS guided biopsy pathological results.

The purpose

Assessing the accuracy of multi parametric magnetic resonance (mp-MRI) after application of PI-RADS V2 for diagnosis of prostate cancer as comparison to pathological results of trans rectal ultra-sound (TRUS) guided biopsy.

Patients and methods

138 prostatic lesions in 23 patients were retrospectively assessed and analyzed with Trans rectal ultra-sound (TRUS) guided biopsy results. Those patients underwent multi parametric magnetic resonance (mp-MRI) with application of PI-RADS V2 reporting system. The sensitivity, specificity, validity, negative predictive value and positive predictive value were calculated for PI-RADS V2 reporting system compared to biopsy-proven pathological results.

Results

92 out of 138 lesions were positive for Peripheral zone cancer prostate. PI-RADS V2 reporting system proved 88.04% sensitive & 93.4% specific for diagnosis of prostate cancer with negative predictive value & positive predictive value of 100%.

Conclusion

Our results proved that mp-MRI of prostate using PI-RADS v2 scoring system had high sensitivity and specificity in diagnosis of prostate cancer and PI-RADS V2 scoring system using mp-MRI is recommended as a non-invasive diagnostic tool compared to TRUS guided biopsy.